Successfully reported this slideshow.
Your SlideShare is downloading. ×

Fast track, incestment spproach and transition funding to end aids epidemic by 2030 manoela manova

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Loading in …3
×

Check these out next

1 of 63 Ad

More Related Content

Slideshows for you (20)

Advertisement

Similar to Fast track, incestment spproach and transition funding to end aids epidemic by 2030 manoela manova (20)

More from PinHealth (20)

Advertisement

Fast track, incestment spproach and transition funding to end aids epidemic by 2030 manoela manova

  1. 1. Manoela Manova Regional Support Team for Eastern Europe and Central Asia
  2. 2. Outline • Fast Track • Rationale for investment approach • Key messages in applying the Investment approach • What is Investment Approach and Investment case • What did we learn from IC implemented so far? • What’s the meaning of transition funding
  3. 3. • Reaching 90/90/90 target - HIV Testing and treatment delivery • Intensified Combination Prevention • Focus on Cities/ location and population programming • Human Rights and Zero Discrimination • Global Plan/EMTCT • Focus, Innovation, Cost savings • Ownership, accountability, leadership
  4. 4. «90-90-90» - ambitious target aimed at ending AIDS In 2020 90% of all people living with HIV will know their HIV status In 2020 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy . In 2020 90% of all people receiving antiretroviral therapy will be virally suppressed
  5. 5. 15 Benefits of fast-tracking the AIDS response in low- and middle-income countries
  6. 6. A SHORT FIVE-YEAR WINDOW
  7. 7. CHOOSE THE WORLD YOU WANT TO SEE IN 2030 BUSINESS AS USUAL ACCELERATED RESPONSE 2.5 million new adult HIV infections 0.2 million new adult HIV infections
  8. 8. What does it take?
  9. 9. Fast-Track the AIDS Response by 2020 Unprecedented Opportunity for HIV Prevention 5 BILLION CONDOMS EVERY YEAR 3 MILLION PEOPLE ON PrEP 2 MILLION YOUNG PEOPLE CASH TRANSFERS 20 MILLION KEY POPULATIONS HIV SERVICES 10 MILLION MEN (ADDITIONAL) MALE CIRCUMCISIONS 25 MILLION PEOPLE ON ART (90-90-90)
  10. 10. Title Slide: title in 24 point Arial regular Estimating resource needs for 90-90-90 in Low and Middle Income Countries Resource Needs for Care and Treatment Service Uptake is Linked to KP Outreach Targets; Treatment Coverage and Quality depends on Programme and Social Enablers $0 $5,000 $10,000 $15,000 $20,000 Resource Needs Millions of US$ ART PreART Testing $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 $35,000 Resource Needs Millions of US$ Health Systems Strengthening Community Mobilization Social Enablers Program Enablers PrEP Prisoners OST PWID Transgenders MSM SW ART PreART Testing
  11. 11. Resource Needs for Ending AIDS by 2030 are the sum of resources to maintain coverage rates as in 2013 and the additional funding to attain ambitious targets. 0.9 0.9 0.9 0.9 0.6 1.0 1.3 1.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 2015 2017 2020 2030 Billions Eastern Europe and Central Asia Constant Coverage Resource Gap
  12. 12. - 2.0 4.0 6.0 8.0 10.0 12.0 14.0 $- $100 $200 $300 $400 $500 $600 $700 2015 2020 2030 Sex Workers Resource needs (millions) Persons to reach (millions) - 5.0 10.0 15.0 20.0 $- $200 $400 $600 $800 $1,000 2015 2020 2030 Men who have sex with men Resource needs (millions) Persons to reach (millions) - 2.0 4.0 6.0 8.0 10.0 12.0 14.0 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 2015 2020 2030 People who inject drugs Persons on Therapy (millions) Persons to reach (millions) Resource needs: OST (millions) Resource needs: outreach (millions) - 2.0 4.0 6.0 8.0 10.0 12.0 $- $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800 $2,000 2015 2020 2030 Pre-Exposure Prophylaxis for MSM, FSW and Adolescents Persons to reach Adolescents Persons to reach KP Resource needs (millions) Reaching out for Key Populations Global targets for key populations The key to attain 90-90-90 is effectively engaging key populations and communities
  13. 13. 1.13 3.60 2.41 1.50 0.69 0.10 3.97 12.39 10.10 6.58 2.67 1.09 Children SDC Multiple partners FSW+clients MSM PWID New infections by Group (Millions) 2015 - 2030 Constant Targets 0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 450,000 New HIV Infections in Key Populations Ambitious Targets 2015 - 2030 FSW+clients MSM PWID The impact of ambitious targets A sharp reduction in new infections for all risk groups
  14. 14. 0 5 10 15 20 25 Total R. Need Total Expenditure Million USD Total resource need and expenditure for CSW, MSM and PWID for a group of 6 countries in 2012 - Armenia, Georgia, Kazakhstan, Kyrgyzstan, Moldova and Uzbekistan. Source: UNAIDS Investment framework ,GARPR 13. Underinvestment in Key Populations Financing Gap for CSW, MSM and PWID in 6 selected Eastern European countries, 2012
  15. 15. Investment approach and Investment case
  16. 16. SYNERGIES WITH DEVELOPMENT SECTORS Social protection; Education; Legal Reform; Gender equality; Poverty reduction; Gender-based violence; Health systems (incl. treatment of STIs, blood safety); Community systems; Employer practices. CRITICAL ENABLERS Social enablers • Political commitment & advocacy • Laws, policies & practices • Community mobilization • Stigma reduction • Mass media • Local responses, to change risk environment Programme enablers • Community-centered design & delivery • Programme communication • Management & incentives • Production & distribution • Research & innovation Care & treatment Male circumcision Keeping more people alive BASIC PROGRAMME ACTIVITIES Key populations Children & mothers Condoms RETURN Less new infections Behaviour change The Case for Optimized Investments
  17. 17. Investment Aproach as Key Opportunity to Optimize for Impact 1. Correct the mismatches between the epidemic and response 2. Focus – geographic, key populations, human rights, etc. 3. Look for allocative efficiencies and efficiencies in the implementation – e.g. avoid systems duplications, scale constraints, service delivery configuration (community services), parallel systems (procurement) 4. Sustainability – manage fiscal space, and domestic and international finance flows for predictability and sustained results.
  18. 18. International resources for HIV have been flat since 2008 Source: UNAIDS, 2012 0 2 4 6 8 10 12 14 16 18 20 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 International assistance US$billions
  19. 19. Middle-income countries have steadily invested more of their own resources in HIV Source: UNAIDS, 2012 0 2 4 6 8 10 12 14 16 18 20 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 International assistance US$billions Domestic resources in low- and middle-income countries
  20. 20. Total resources continue to grow, but fall short of total needs Source: UNAIDS, 2012 0 2 4 6 8 10 12 14 16 18 20 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 International assistance Total resources available, with estimated range US$billions Domestic resources in low- and middle-income countries
  21. 21. Key message 1: Every dollar spent on AIDS is an investment not expenditure and countries can make important gains if they invest wisely, now
  22. 22. Key message 2: Focus on what makes a difference - Investing resources strategically for greater impact
  23. 23. Using a geographic approach to prioritize investment – Thailand - location • Thailand: Thailand intends to scale up combination prevention , including the strategic use of antiretroviral medicines, with enhanced focus on the 27 provinces that represent 70% of all new HIV infections among key populations
  24. 24. Morocco: Reallocating to invest where the epidemic is Source: Morocco Ministry of Health, National STI/HIV Programme, HIV modes of transmission in Morocco. August 2010. General population Sex workers and clients MSM IDU Key populations (other) Percentage(%) 80 0 Proposed spending, National Strategic Plan for 2012–2016 People acquiring HIV infection (2009) Spending on HIV prevention (2008)
  25. 25. Source: UNAIDS Number of new HIV infections 300 000 1980 1990 2000 2010 Russian Federation Brazil Investing smart is a choice
  26. 26. Eastern Europe and Central Asia Concentrated HIV epidemics, in particular in PWID HIV prevalence in selected populations in Eastern Europe and Central Asia, 2011 Source: UNAIDS 2012
  27. 27. Spending on harm reduction for IDUs of total response (International & Public/ domestic Funding without private) Country Year % spending on harm reduction for IDUs of total response (International & Public/ domestic Funding without private) Armenia 2011 8% Azerbaijan 2011 4% Belarus 2011 9% Georgia 2011 23% Kazakhstan 2011 7% Kyrgyzstan 2011 7% Republic of Moldova 2011 8% Russian Federation 2008 1% Tajikistan 2011 9% Ukraine 2010 5% Uzbekistan 2011 5%
  28. 28. Key message 3: Address service delivery, cost drivers and bottlenecks to scale up
  29. 29. Successful country initiatives to lower ARV costs Country Action Savings South Africa • Revised tender process to increase competition • Pooled procurement across provinces to achieve economies of scale • Improved price transparency $640 million over 2 years Uganda • Ring-fenced ARV funds • Regularly monitored ARV market prices • Promptly switched to approved generics $1.3 million between 2006 and 2007 Swaziland • Revised ARV tender process, included ceiling prices, supplier performance and more reliable quantification methods $12 million between January 2010 and March 2012 Nigeria • Coordinated with PEPFAR implementing partners for ARV planning, purchase, shipping and distribution of ARVs. • Transferred ARVs between partners to avoid stock- outs, costly emergency orders and wastage due to expired drugs $2.8 million in drug costs since May 2010 Brazil • Implemented compulsory license for the manufacture of efavirenz $95 million
  30. 30. Practical Quick Savings that can be made Number of Patients on ART in Russia Average Cost of ART drugs per patient per year in USD paid by Russia TOTAL costs of ART drugs per year (in USD) 160,000 2,500 400,000,000 Number of Patients on ART in Russia Cipla Cost of ART drugs per patient per year in USD TOTAL costs of ART drugs per year (in USD) 160,000 225 36,000,000 What could be yearly savings for the Government of Russia 364,000,000 How many patients could the Government treat with the same yearly allocation if using Cipla prices Cipla Cost of ART drugs per patient per year in USD TOTAL costs of ART drugs per year (in USD) 1,777,778 225 400,000,000
  31. 31. Practical Quick Savings that can be made Number of Patients on ART in Russia Number of VL per patient per year Approximate Price paid by Russian Government for one VL (in USD) TOTAL costs of VL paid by Russia per year (in USD) 160,000 4 69 44,160,000 Number of Patients on ART in Russia Number of VL per patient per year Reduced VL price For e.g. Roche Global Access initiative price (in USD) TOTAL costs of VL paid by Russia per year (in USD) 160,000 2 10 3,200,000 What could be yearly savings for the Government of Russia 40,960,000
  32. 32. Unit expenditure benchmarking: PEPFAR: Use of Expenditure Analysis Results for Partner Management to Improve Efficiency Goal to ensure IPs that are providing similar services/support are adopting best practices and using PEPFAR resources optimally Step 1: Identify outliers Step 2: In–depth analysis to identify cost drivers Step 3: Agreement to lower UE by $X in coming year by decreasing expenditures or increasing targets Source: PEPFAR Finance and Economics Work Group
  33. 33. Regional averages of Unit Costs for Prevention Interventions in EECA: much higher than projected global costs 0.0 20.0 40.0 60.0 80.0 100.0 120.0 2009 2015 2009 2015 2009 2015 2009 2015 2009 2015 Sex Worker Outreach Counseling & Testing IDU Outreach & NSEP MSM Outreach STI Treatment Eastern Europe Global Average Source: Bollinger & Stover, 2009 USD
  34. 34. Integrated services are more efficient USD 0 5 10 15 20 25 30 35 40 Kenya (2002) Kenya (2008) India (2007) Uganda (2009) stand-alone C&T (e.g. HIV clinics) C&T integrated (e.g. SRH/FP or PHC clinics) The example of VCT: Costs per client Stand-alone VCT clinics Integrated into SRH services
  35. 35. Key message 4: Making HIV responses sustainable is a shared responsibility
  36. 36. OECD countries can afford to do more 2010 overseas development assistance as a share of Gross National Income 0.12% 0.15% 0.17% 0.20% 0.21% 0.26% 0.29% 0.32% 0.32% 0.33% 0.38% 0.41% 0.43% 0.50% 0.53% 0.55% 0.56% 0.64% 0.81% 0.90% 0.97% 1.09% 1.10% 0.0% 0.7% Korea Italy Greece Japan United States New Zealand Portugal Australia Austria Canada Germany switzerland Spain France Ireland Finland United Kingdom Belgium Netherlands Denmark Sweden Luxembourg Norway 0.12% 0.15% 0.17% 0.20% 0.21% 0.26% 0.29% 0.32% 0.32% 0.33% 0.38% 0.41% 0.43% 0.50% 0.53% 0.55% 0.56% 0.64% 0.81% 0.90% 0.97% 1.09% 1.10% 0.0% 0.7% Korea Italy Greece Japan United States New Zealand Portugal Australia Austria Canada Germany switzerland Spain France Ireland Finland United Kingdom Belgium Netherlands Denmark Sweden Luxembourg Norway
  37. 37. Middle-income countries will provide more HIV resources Note: Based on ability to pay, by income category, and allocation to HIV in line with disease burden. Data sourced from the IMF and including UNAIDS projections. 0 5 10 15 20 25 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 International contribution Low income countries Lower middle Upper middle (non-BRICS) BRICS US$billion
  38. 38. HIV investment case:
  39. 39. What Investment Approach (IA) and Investment case (IC) mean? • Investment Approach is a process of rigorous examination of HIV responses in terms of effectiveness, efficiency, and sustainability • Investment case is the application of the HIV investment approach. IC is a document based on investment logic and reviews of HIV responses in terms of effectiveness, efficiency, and sustainability to estimate returns of investments - new HIV infections averted and Deaths averted. • IC is aimed to answer specific policy questions that are of high priority for the country. • IC provides different scenarios that allow the decision makers to weigh various options and make informed decisions on funding for specified outcomes.
  40. 40. Same Same, but Different – NSP -IC • While there is significant overlap between robust NSPs and investment cases in the sense that investment cases are also evidence- based documents providing essential information on the epidemiological context, the current response, and other key areas, a sound investment case quantifies the returns on HIV investments. NSPs rarely include such an assessment. Investment cases also have a longer-term perspective (typically 10+ years), which is crucial, as returns of investments often occur beyond the 5-year horizon of a NSP.
  41. 41. An investment case answers 8 critical questions UNDERSTAND DESIGN DELIVER SUSTAIN ▪ Introduction: Why an investment case now?0 ▪ What is the current state of the epidemic? And how is that expected to change? 1 ▪ Where are we focusing our efforts and resources today? What is the current impact? And where does the money come from? 2 ▪ What programme elements are required and at what scale for an optimal response? 3 ▪ What would the impact of this optimal programme be?4 ▪ How much money will be needed for HIV in the future and what are the net savings over time? 6 ▪ What bottlenecks and inefficiencies can be addressed and how?5 ▪ What financing options are available to close any remaining financing gap once efficiency gains are achieved? 7 ▪ How will you guarantee stakeholder buy-in and operational excellence required? 8 INVESTMENT CASE TOOL
  42. 42. Your investment case should allow you to complete this summary pageExample output: Improved HIV response WHAT IS AN INVESTMENT CASE? Net savings (through treatment and hospitalization costs averted) $600 million Current programme 85,000 Resource needs for business as usual over the next decade (based on current plan) Total number of new infections averted $600 million 98,000 Total number of deaths averted Optimal programme Costs required over the next decade for optimal investment of resources (accounting for enhanced investments and efficiency gains) $900 million deaths averted 135,000 Total number of new infections averted 176,000 Total number of deaths averted 1,165 Cost / infection averted ILLUSTRATIVE
  43. 43. Optimal allocation o Depends on objective o Minimizing new infections is only one objective o Different objectives = different allocations o Universal access to HIV services and Equality in access to prevention services and health care across all groups is a different objective o Other governing principles and strategies are important that achieve different objectives
  44. 44. What we do in the region to improve the value for money • We promote the Investment approach and develop investment cases • We conduct Allocative Efficiency Analysis • We plan technical efficiency studies to identify the most cost efficient service delivery models • We engage in ART and VL tests price reduction negotiations • We estimate resource and service gaps to scale up to 90-90- 90 targets in the region
  45. 45. Kazakhstan Allocative Efficiency Findings Optimize spending towards national and ambitious targets National targets - keep the HIV new infections/deaths in 2020 at 2014 level Ambitious targets - reduce HIV new infections/deaths by 2020 to 50% of 2014 levels
  46. 46. New HIV infections under different investment scenarios
  47. 47. Total number of AIDS-related deaths over time
  48. 48. Number people receiving treatment
  49. 49. Kazakhstan Allocative Efficiency Findings With current ART prices Kazakstan cannot achieve national targets with current funding, even if optimally allocated However, reducing ART three-fold would allow to achieve the ambitious targets with existing funding (and 20% efficiency gains
  50. 50. Countries can achieve more with less – example of Armenia Expected impact of different resource allocations 75 additional HIV infections 124 averted HIV infections 20% reduction in infections would occur with a 22.2% decrease in overall funding if allocated optimally
  51. 51. Conclusion: What did we learn?
  52. 52. Challenges, emerging lessons and recommendations for moving forward • IC - Inherently political process that requires difficult decisions regarding resource allocations. • Vested interests that have previously leveraged their political power to capture a share of resources may resist efforts to re- think resource allocations or expose decisions about allocations to rigorous examination. • The measure for success - ensuring that tough decisions are actually implemented.
  53. 53. Challenges, emerging lessons and recommendations for moving forward • Capacity challenges - Most countries are currently relying on external experts for modelling, estimation, projections and economic analysis: an approach that is clearly not sustainable over the long run. • Moreover, decentralisation, strengthening community systems and eliminating parallel service systems – while beneficial from the standpoint of the long-term return on investment – will often require considerable start-up costs and will not be achieved overnight. • Currently, a major gap in available evidence in many countries concerns the actual costs of HIV services.
  54. 54. Transition funding possibilities
  55. 55. What’s the meaning of transition? • From a context in which central/local governments and the Fund supply jointly a predominant majority of funding for the national AIDS response • To a context in which central/local governments alone supply a predominant majority of funding for the national AIDS response. • The key risk that the transition plan is meant to mitigate maintain the variety, scope, and scale of HIV prevention and treatment programs and that the implementation capacity that delivers the services funded by the Fund is used by the governments.
  56. 56. Romania’s fate!? • Ineligible since Round 7. Disbursements stopped in 2010. • Coverage of PWID fell from 76% in 2009 to 49% in 2011. Nearly all NEPs had to close by mid-2013. ROMANIA 2010 2011 2012 2013 New HIV cases in IDU 9 116 170 149 New HIV cases in MSM 45 78 69 72 HIV rate per 100,000 general population 1.4 2.1 2.4 2.5 Source: ERHN, ECDC
  57. 57. Why not Russia’s fate!? • Applied under NGO rule in 2014 • As of 1 January 2015, previously funded by GFATM programs, i.e., 30 NSP prog. (27,000 clients), 5 CSW prog. (3,350 clients), 5 MSM prog. (4,200 clients) will cease to receive commodities and funds. • As of 1 November 2014: • 864 394 registered HIV cases • 63 863 newly registered in 2014 • 58,4% due to injecting drug use Source: GFATM, Russian Federal AIDS Centre
  58. 58. What the transition plan is meant to? • Rules are different for GFATM and public funds • Parallel systems • Not necessarily bad, if both can deliver complimentary services, have two different sources of funding that cannot be unified • Collapse if one cannot do what the other can, and should one of the two disappear • To help public health systems learn to fund what GF funds
  59. 59. Critical leverage point • Transition is a tailor-made process • Critical leverage point: counterpart financing • Ability to spend public monies on the same program as the Global Fund – a true stress test of recipient countries’ readiness to graduate. • Graduation is not optional
  60. 60. Pillars of graduation • Legislative acts & normative documents that enable central/local governments spend public funds: • on HIV prevention in key populations & settings • to purchase services of NGOs to prevent HIV in key populations
  61. 61. Government & International funding for ART & Prevention in 2012 $0 $5,000,000 $10,000,000 $15,000,000 $20,000,000 $25,000,000 Prevention ART Prevention ART Prevention ART Prevention ART Prevention ART Prevention ART Uzbekistan Belarus Moldova Kazakhstan Romania Turkey international public Source: GARPR 2013
  62. 62. Public funds to purchase services of NGOs • Laws and implementation mechanisms exist in many countries but: –May not apply to HIV prevention (Belarus) –No implementation mechanism (Moldova) –Will need constant modification during “learning” period (Kazakhstan)
  63. 63. In order to make a breakthrough in AIDS response we need to “Maximize the effectiveness of existing tools to virtually eliminate progression to AIDS, premature death and HIV transmission, and thereby transform the HIV/AIDS pandemic into a low level sporadic endemic.”

×